Protara Therapeutics, Inc. announced on December 3, 2025, they shared positive interim results from their ADVANCED-2 Trial for TARA-002, showing a 72% complete response rate in patients with non-muscle invasive bladder cancer. This is a significant event as it supports the treatment's potential effectiveness and is discussed in detail in their investor presentation and press release.